Skin Aging
Also known as: Senile, Senilis
Methodology & AI Transparency ⓘ
Skin Aging Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your skin changes as you age.
- 2 Real-world patient consensus: Synonyms for Skin Aging (D69.2): Senile, Senilis (Blood & Anemia).
- 3 Typical cash cost range: Workup highlights for Skin Aging (D69.2): targeted oral/IV iron in Skin Aging (D69.2: or vitamin repletion).
- 4 Top reported side effects / signs: Longitudinal Skin Aging monitoring tracks Hemoglobin, Hematocrit & in Skin Aging (D69.2: MCV) toward Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D69.2).
Ask our AI Specialists anything about Skin Aging
What Is Skin Aging?
Your skin changes as you age. You might notice wrinkles, age spots and dryness. Your skin also becomes thinner and loses fat, making it less plump and smooth. It might take longer to heal, too. Sunlight is a major cause of skin aging. You can protect yourself by staying out of the sun when it is strongest, using sunscreen with an SPF of 15 or higher, wearing protective clothing, and avoiding sunlamps and tanning beds. Cigarette smoking also contributes to wrinkles. The wrinkling increases with the amount of cigarettes and number of years a person has smoked.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Skin Aging (D69.2) center on impaired erythropoiesis from in Skin Aging (D69.2: iron). Cross-referenced with NIH MeSH (Skin Aging), targeted blood & anemia interventions aim to normalize Hemoglobin, Hematocrit & in Skin Aging (D69.2: MCV).
Common Symptoms & Clinical Signs
- • Presentation of Skin Aging (D69.2): exertional fatigue, reduced in Skin Aging (D69.2: stamina, pale conjunctiva,)
- • Secondary Skin Aging clinical sign: restless legs, ice in Skin Aging (D69.2: craving)
- • Symptom flares in Skin Aging correlating with Hemoglobin, Hematocrit & in Skin Aging (D69.2: MCV) deviation outside Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D69.2)
- • Functional blood & anemia impact requiring targeted oral/IV iron in Skin Aging (D69.2: or vitamin repletion) evaluation (D69.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Skin Aging Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D69.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Skin Aging (D69.2: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D69.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Skin Aging (D69.2: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D69.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Skin Aging (D69.2: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D69.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Skin Aging
Treatment selection for Skin Aging depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Skin Aging)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is: What a 1,272-Participant Study Found LetibotulinumtoxinA significantly improved the psychosocial burden associated with glabellar lines across all trials. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2024-06-01 • Phase III Randomized Trial | N = 1,272 | 96/100 | PMID 38470985 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Phase I/III Clinical Trial to Evaluate the safety and real-world benefits of a: What a 290-Participant Study Found HU-014 has noninferior real-world benefits and safety compared with onabotulinumtoxinA in the treatment of CFL. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2021-04-01 • Phase III Randomized Trial | N = 290 | 93/100 | PMID 33795571 ↗ |
Skin Aging Patient Community & “People Like Me” Threads
Filter Skin Aging community threads and patient logs by age, biological sex, dosage, and treatment duration.